Search

Your search keyword '"Amerio, Paolo"' showing total 14 results
Start Over Author "Amerio, Paolo" Publication Type Electronic Resources
14 results on '"Amerio, Paolo"'

1. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study

Author

Stingeni,Luca, Malara,Giovanna, Conti,Andrea, Di Costanzo,Luisa, Carrera,Carlo Giovanni, Burlando,Martina, Malagoli,Piergiorgio, Musumeci,Maria Letizia, Bardazzi,Federico, Brazzelli,Valeria, Amerio,Paolo, De Simone,Clara, Trevisini,Sara, Balato,Anna, Megna,Matteo, Loconsole,Francesco, De Felice,Catia, Bartezaghi,Marta, Rausa,Alice, Aloisi,Elisabetta, Orsenigo,Roberto, Costanzo,Antonio, Stingeni,Luca, Malara,Giovanna, Conti,Andrea, Di Costanzo,Luisa, Carrera,Carlo Giovanni, Burlando,Martina, Malagoli,Piergiorgio, Musumeci,Maria Letizia, Bardazzi,Federico, Brazzelli,Valeria, Amerio,Paolo, De Simone,Clara, Trevisini,Sara, Balato,Anna, Megna,Matteo, Loconsole,Francesco, De Felice,Catia, Bartezaghi,Marta, Rausa,Alice, Aloisi,Elisabetta, Orsenigo,Roberto, and Costanzo,Antonio

Abstract

Luca Stingeni,1 Giovanna Malara,2,3 Andrea Conti,4 Luisa Di Costanzo,5 Carlo Giovanni Carrera,6 Martina Burlando,7 Piergiorgio Malagoli,8 Maria Letizia Musumeci,9 Federico Bardazzi,10 Valeria Brazzelli,11 Paolo Amerio,12 Clara De Simone,13,14 Sara Trevisini,15 Anna Balato,16 Matteo Megna,17 Francesco Loconsole,18 Catia De Felice,19 Marta Bartezaghi,20 Alice Rausa,20 Elisabetta Aloisi,20 Roberto Orsenigo,20 Antonio Costanzo21,22 On behalf of the SUPREME Study Group1Dermatology Section, Medical and Surgical Department, University of Perugia, Perugia, Italy; 2Dermatology Unit, Hospital “Bianchi Melacrino Morelli”, Reggio Calabria, Italy; 3Department of Dermatology, Papardo Hospital, Messina, Italy; 4Dermatologic Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, Rimini, Italy; 5Department of Dermatology, “Gaetano Rummo” Hospital, Benevento UOC Dermatologia, AO G. Rummo, Benevento, Italy; 6U.O. Dermatologia, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milano, Italy; 7IRCCS San Martino Polyclinic Hospital, Di.S.Sal. Section of Dermatology, Genoa, Italy; 8Dermatology Unit IRCCS Policlinico San Donato, Milan, Italy; 9Dermatology Clinic, University of Catania, Catania, Italy; 10Division of Dermatology, University Hospital Policlinico “S. Orsola-Malpighi”, Bologna, Italy; 11Institute of Dermatology, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy; 12Dermatologic Clinic, G. D’Annunzio University, Chieti, Italy; 13Istituto di Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy; 14Fondazione Policlinico Universitario A. Gemelli – IRCCS, Rome, Italy; 15Dermatology Department, University of Trieste, Trieste, Italy; 16Dermatology Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy; 17Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 18Department of Biomedical Sciences and Human Oncology, University of Bari, Bari

Published
2023

2. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), De Simone, Clara (ORCID:0000-0002-0898-0045), Peris, Ketty (ORCID:0000-0002-5237-0463), Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), De Simone, Clara (ORCID:0000-0002-0898-0045), and Peris, Ketty (ORCID:0000-0002-5237-0463)

Published
2022

3. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), De Simone, Clara (ORCID:0000-0002-0898-0045), Peris, Ketty (ORCID:0000-0002-5237-0463), Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), De Simone, Clara (ORCID:0000-0002-0898-0045), and Peris, Ketty (ORCID:0000-0002-5237-0463)

Published
2022

4. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), De Simone, Clara (ORCID:0000-0002-0898-0045), Peris, Ketty (ORCID:0000-0002-5237-0463), Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), De Simone, Clara (ORCID:0000-0002-0898-0045), and Peris, Ketty (ORCID:0000-0002-5237-0463)

Published
2022

5. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Valerio Marzano, Angelo, Girolomoni, Giampiero, Offidani, Annamaria, Teresa Rossi, Maria, Bianchi, Luca, Cristaudo, Antonio, Teresa Fierro, Maria, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Rita Bongiorno, Maria, Grieco, Teresa, Di Nuzzo, Sergio, Concetta Fargnoli, Maria, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Mariel Ferrucci, Silvia, Guarneri, Fabrizio, Peris, Ketty, Andrea Chiricozzi (ORCID:0000-0002-6739-0387), Lucia Di Nardo, Clara De Simone (ORCID:0000-0002-0898-0045), Flaminia Antonelli, Ketty Peris (ORCID:0000-0002-5237-0463), Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Valerio Marzano, Angelo, Girolomoni, Giampiero, Offidani, Annamaria, Teresa Rossi, Maria, Bianchi, Luca, Cristaudo, Antonio, Teresa Fierro, Maria, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Rita Bongiorno, Maria, Grieco, Teresa, Di Nuzzo, Sergio, Concetta Fargnoli, Maria, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Mariel Ferrucci, Silvia, Guarneri, Fabrizio, Peris, Ketty, Andrea Chiricozzi (ORCID:0000-0002-6739-0387), Lucia Di Nardo, Clara De Simone (ORCID:0000-0002-0898-0045), Flaminia Antonelli, and Ketty Peris (ORCID:0000-0002-5237-0463)

Abstract

N/A

Published
2022

6. Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy

Author

Argenziano,Giuseppe, Amerio,Paolo, Aragone,Maria Grazia, Baggini,Ginevra, Baldari,Manuela, Castelli,Gianpiero, Coppola,Simmaco, Costanzo,Antonio, De Pasquale,Rocco, Fargnoli,Maria Concetta, Foti,Caterina, Giofrè,Claudia, Lembo,Serena, Leporati,Claudia, Loconsole,Francesco, Malara,Giovanna, Peris,Ketty, Richetta,Antonio Giovanni, Savoia,Paola, Tiberio,Rossana, Travaglini,Massimo, Uzzauto,Maria Teresa, Bianchi,Luca, Argenziano,Giuseppe, Amerio,Paolo, Aragone,Maria Grazia, Baggini,Ginevra, Baldari,Manuela, Castelli,Gianpiero, Coppola,Simmaco, Costanzo,Antonio, De Pasquale,Rocco, Fargnoli,Maria Concetta, Foti,Caterina, Giofrè,Claudia, Lembo,Serena, Leporati,Claudia, Loconsole,Francesco, Malara,Giovanna, Peris,Ketty, Richetta,Antonio Giovanni, Savoia,Paola, Tiberio,Rossana, Travaglini,Massimo, Uzzauto,Maria Teresa, and Bianchi,Luca

Abstract

Giuseppe Argenziano,1,* Paolo Amerio,2 Maria Grazia Aragone,3 Ginevra Baggini,4 Manuela Baldari,5 Gianpiero Castelli,6 Simmaco Coppola,7 Antonio Costanzo,8,9 Rocco De Pasquale,10 Maria Concetta Fargnoli,11 Caterina Foti,12 Claudia Giofrè,13 Serena Lembo,14 Claudia Leporati,15,16 Francesco Loconsole,17 Giovanna Malara,18 Ketty Peris,19,20 Antonio Giovanni Richetta,21 Paola Savoia,22 Rossana Tiberio,23 Massimo Travaglini,24 Maria Teresa Uzzauto,25 Luca Bianchi26,* 1Dermatology Unit, University of Campania, Naples, Italy; 2Department of Medicine and Aging Science and Dermatologic Clinic, University “G. d’Annunzio”, Chieti-Pescara, Chieti, Italy; 3ASL AL, Alessandria, Italy; 4Osp. Civile di Varzi, Pavia, Italy; 5ASL4 Liguria, Genova, Italy; 6UOSD of Dermatology, Ospedale Umberto I°, Siracusa, Italy; 7IQVIA, Rome, Italy; 8Department of Biomedical Sciences, Humanitas University, Milano, Italy; 9Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Milano, Italy; 10UOC Dermatologia, AOU Policlinico “G. Rodolico – San Marco”, Catania, Italy; 11Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 12Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, Bari, Italy; 13U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; 14Dipartimento di Medicina, Chirurgia e Odontoiatria Scuola Medica Salernitana, University of Salerno, Fisciano, Italy; 15Dermatology Unit, ASL AL Casale Monferrato, Alessandria, Italy; 16Dermatology Unit, ASL TO4 Ivrea, Torino, Italy; 17Department of Dermatology, University of Bari, Bari, Italy; 18UOC of Dermatology, Grande Ospedale Metropolitano “BMM”, Reggio Calabria, Italy; 19Institute of Dermatology, Catholic University, Rome, Italy; 20Dermatology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 21Dipartim

Published
2021

7. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

Author

Chiricozzi, Andrea, Talamonti, Marina, De Simone, Clara, Galluzzo, Marco, Gori, Niccolò, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Di Nardo, Lucia, Guarneri, Fabrizio, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), De Simone, Clara (ORCID:0000-0002-0898-0045), Peris, Ketty (ORCID:0000-0002-5237-0463), Chiricozzi, Andrea, Talamonti, Marina, De Simone, Clara, Galluzzo, Marco, Gori, Niccolò, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Di Nardo, Lucia, Guarneri, Fabrizio, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), De Simone, Clara (ORCID:0000-0002-0898-0045), and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic.Methods A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity.Results A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred.Conclusions Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.

Published
2021

8. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Author

Gisondi, Paolo, Talamonti, Marina, Chiricozzi, Andrea, Piaserico, Stefano, Amerio, Paolo, Balato, Anna, Bardazzi, Federico, Calzavara Pinton, Piergiacomo, Campanati, Anna, Cattaneo, Angelo, Dapavo, Paolo, De Simone, Clara, Dini, Valentina, Fargnoli, Maria Concetta, Flori, Maria L, Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Loconsole, Francesco, Lo Schiavo, Ada, Malagoli, Piergiorgio, Malara, Giovanna, Mercuri, Santo R, Musumeci, Maria L, Naldi, Luigi, Papini, Manuela, Parodi, Aurora, Potenza, Concetta, Prignano, Francesca, Rongioletti, Franco, Stingeni, Luca, Tiberio, Rossana, Venturini, Marina, Bianchi, Luca, Costanzo, Antonio, Cusano, Francesco, Girolomoni, Giampiero, Offidani, Anna M, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), De Simone, Clara (ORCID:0000-0002-0898-0045), Fargnoli, Maria C, Peris, Ketty (ORCID:0000-0002-5237-0463), Gisondi, Paolo, Talamonti, Marina, Chiricozzi, Andrea, Piaserico, Stefano, Amerio, Paolo, Balato, Anna, Bardazzi, Federico, Calzavara Pinton, Piergiacomo, Campanati, Anna, Cattaneo, Angelo, Dapavo, Paolo, De Simone, Clara, Dini, Valentina, Fargnoli, Maria Concetta, Flori, Maria L, Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Loconsole, Francesco, Lo Schiavo, Ada, Malagoli, Piergiorgio, Malara, Giovanna, Mercuri, Santo R, Musumeci, Maria L, Naldi, Luigi, Papini, Manuela, Parodi, Aurora, Potenza, Concetta, Prignano, Francesca, Rongioletti, Franco, Stingeni, Luca, Tiberio, Rossana, Venturini, Marina, Bianchi, Luca, Costanzo, Antonio, Cusano, Francesco, Girolomoni, Giampiero, Offidani, Anna M, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), De Simone, Clara (ORCID:0000-0002-0898-0045), Fargnoli, Maria C, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Introduction: Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project 'Treat to Target Italia' was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations. Methods: On the basis of the published literature, their clinical experience, and the results of a survey among Italian dermatologists, the SB identified four relevant topics: (1) clinical remission; (2) quality of life; (3) abrogation of systemic inflammation; (4) safety. They drafted 20 statements addressing these four topics and submitted them to a panel of 28 dermatologists, in a Delphi process, to achieve consensus (greater than 80% agreement). Results: Consensus was reached on all statements. Treatment goals defining clinical remission should include a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI90 response) or an absolute PASI score of less than or equal to 3. Patient's quality of life and satisfaction are important targets. If PASI targets are achieved, there should be no or very low impact of psoriasis on quality of life [Dermatology Life Quality Index (DLQI) score less than or equal to 3]. If PASI or DLQI goals are not achieved within 3-4 months, treatment should be changed. Abrogation of systemic inflammation may be crucial for preventing or delaying inflammatory comorbidities. Safety is an equally important target as efficacy. Conclusion: These 20 consensus statements define the parameters of a treat-to-target strategy for psoriasis in Italy. It is hoped that use of these in the management of patients with psoriasis will improve treatment outcomes and patient health-related quality of life.

Published
2021

9. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

Author

Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iri, Bianchi, Luca, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), Zalaudek, Iris, Peris, Ketty (ORCID:0000-0002-5237-0463), Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iri, Bianchi, Luca, Peris, Ketty, Chiricozzi, Andrea (ORCID:0000-0002-6739-0387), Zalaudek, Iris, and Peris, Ketty (ORCID:0000-0002-5237-0463)

Abstract

Background: The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods: Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results: A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen 'cytokine storm' of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

Published
2021

10. Extraordinary and prolonged Erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report

Author

Gambale,Elisabetta, Carella,Consiglia, Amerio,Paolo, Buttitta,Fiamma, Patea,Rosa Lucia, Natoli,Clara, De Tursi,Michele, Gambale,Elisabetta, Carella,Consiglia, Amerio,Paolo, Buttitta,Fiamma, Patea,Rosa Lucia, Natoli,Clara, and De Tursi,Michele

Abstract

Elisabetta Gambale,1 Consiglia Carella,1 Paolo Amerio,2 Fiamma Buttitta,3 Rosa Lucia Patea,4 Clara Natoli,1 Michele De Tursi1 1Medical Oncology Unit, Department of Medical, Oral and Biotechnological Sciences, 2Department of Dermatology and Venereology, University G. d’Annunzio, Chieti, 3Department of Medicine and Aging Sciences, University of Chieti-Pescara, Chieti, 4Department of Radiologic Sciences, University of Chieti-Pescara, Chieti, Italy Abstract: Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly improve clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but erlotinib activity in EGFR wild-type squamous carcinoma is still highly debated. Here, we describe a prolonged and unexpected clinical response to erlotinib in a male former heavy cigarette smoker with wild-type EGFR squamous-cell cancer. Keywords: erlotinib, squamous NSCLC, EGFR wild type

Published
2017

11. Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts

Author

De Tursi,Michele, Zilli,Marinella, Carella,Consiglia, Auriemma,Matteo, Lisco,Maria Nadia, Di Nicola,Marta, Di Martino,Giuseppe, Natoli,Clara, Amerio,Paolo, De Tursi,Michele, Zilli,Marinella, Carella,Consiglia, Auriemma,Matteo, Lisco,Maria Nadia, Di Nicola,Marta, Di Martino,Giuseppe, Natoli,Clara, and Amerio,Paolo

Abstract

Michele De Tursi,1 Marinella Zilli,1 Consiglia Carella,1 Matteo Auriemma,2 Maria Nadia Lisco,2 Marta Di Nicola,3 Giuseppe Di Martino,4 Clara Natoli,1 Paolo Amerio2 1Department of Medical, Oral and Biotechnological Sciences, Medical Oncology Unit, 2Department of Dermatology and Venereology, 3Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, 4Department of Medicine and Aging Science, University degli Studi “G d’Annunzio” Chieti-Pescara, Chieti, Italy Objectives: The effectiveness of evaluation of the severity of epidermal growth-factor receptor inhibitor (EGFRI)-associated dermatological toxicities remains a topic of debate. This study was designed to assess the correlation between quality of life (QoL) and severity of dermatological toxicity, evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) and our novel scale, the Eruption Scoring System (ESS), in metastatic colorectal cancer (CRC) patients treated with first-line chemotherapy combined with cetuximab. Methods: Cutaneous toxicity was evaluated, by oncologists and dermatologists, in patients (n=30) with histologically confirmed metastatic CRC who were scheduled to begin first-line chemotherapy combined with the EGFRI, cetuximab, using the NCI-CTCAE and ESS tools. Health-related QoL (HRQoL) was evaluated using the Skindex-29 and Skindex-17 dermatology-specific instruments. Correlations between QoL and skin toxicity severity were assessed using Spearman’s rank tests. Interclass correlation coefficients were used to assess interoperator agreement for ESS and NCI-CTCAE v4.0 scoring. Results: A positive correlation was identified between dermatology HRQoL and the severity of dermatological toxicities assessed using the NCI-CTCAE v4.0 scale for cutaneous papulopustular acneiform rash; however, a stronger correlation was observed between HRQoL and toxicities evaluated using the ESS

Published
2017

13. Psoriasis awareness among Italian patients: results of a nationwide survey

Author

Bardazzi, Federico, Amerio, Paolo, Amoruso, Giuseppe, Campanati, Anna, Conti, Andrea, De Simone, Clara, Gisondi, Paolo, Gualdi, Giulio, Guarneri, Claudio, Loconsole, Francesco, Mazzotta, Annamaria, Musumeci, Maria L, Piaserico, Stefano, Potenza, Concetta, Scudeller, Luigia, De Simone, Clara (ORCID:0000-0002-0898-0045), Bardazzi, Federico, Amerio, Paolo, Amoruso, Giuseppe, Campanati, Anna, Conti, Andrea, De Simone, Clara, Gisondi, Paolo, Gualdi, Giulio, Guarneri, Claudio, Loconsole, Francesco, Mazzotta, Annamaria, Musumeci, Maria L, Piaserico, Stefano, Potenza, Concetta, Scudeller, Luigia, and De Simone, Clara (ORCID:0000-0002-0898-0045)

Abstract

n/A

Published
2016

14. Polyglandular autoimmune diseases in a dermatological clinical setting: vitiligo-associated autoimmune diseases

Author

Amerio, Paolo, Di Rollo, D, Carbone, A, Auriemma, M, Marra, Me, De Remigis, P, Feliciani, Claudio, Tracanna, M, Tulli, A., Amerio, Paolo, Di Rollo, D, Carbone, A, Auriemma, M, Marra, Me, De Remigis, P, Feliciani, Claudio, Tracanna, M, and Tulli, A.

Abstract

Vitiligo is an acquired hypomelanotic disorder characterized by depigmented macules resulting from the loss of functional melanocytes. Many different etiological hypotheses have been suggested for vitiligo, the most recent of which involves a combination of interacting environmental and genetic factors. Among the various pieces of evidence in support of an autoimmune origin of vitiligo, there is the epidemiological association with several autoimmune diseases. The most frequently reported association is with autoimmune thyroiditis; however, other diseases such as rheumatoid arthritis, diabetes mellitus, pernicious anemia and chronic urticaria have been described in variable percentages, depending upon the genetics of the population studied. Among the diseases described in association with vitiligo there are the so-called autoimmune polyglandular syndromes (APS). Here we report 31 cases of APS diagnosed in 113 vitiligo patients, according to the newest classification. Autoimmune association was more present in generalized non segmental vitiligo and was more frequent in females. The most frequent association was with thyroid autoimmune disease, followed by autoimmune gastritis and alopecia areata. ANA positivity was similar to that reported previously in the general population. We stress the importance of an assessment for autoimmune diseases in vitiligo patients.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results